Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARROW: [68Ga]-LNTH-2401 PET/CT Imaging in Prostate Cancer
NCT07831824Phase 3Recruiting
- Sponsor
- Lantheus Holdings, Inc.
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of [68Ga]-LNTH-2401 in prostate cancer (PCa), sponsored by Lantheus Holdings, Inc. Primary endpoints: Optimal administered activity and imaging time window for [68Ga]-LNTH-2401 PET/CT at Day 1, Biodistribution and radiation dosimetry of [68Ga]-LNTH-2401 at Day 1 and 2 more. Started Sep 2026; status: recruiting.
02
Drugs
[68Ga]-LNTH-2401
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07831824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07831824.